Media coverage about VBI Vaccines (NASDAQ:VBIV) has trended somewhat negative on Thursday, Accern reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. VBI Vaccines earned a coverage optimism score of -0.07 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.2041864613574 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Several research analysts have recently weighed in on VBIV shares. Noble Financial reaffirmed a “buy” rating on shares of VBI Vaccines in a research note on Friday, March 23rd. Zacks Investment Research raised VBI Vaccines from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research note on Saturday, December 23rd. Finally, BidaskClub downgraded VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Three equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. VBI Vaccines presently has an average rating of “Hold” and an average target price of $8.75.
Shares of VBIV traded down $0.11 during trading hours on Thursday, hitting $3.52. 71,640 shares of the stock were exchanged, compared to its average volume of 115,567. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.26 and a current ratio of 5.32. VBI Vaccines has a 12-month low of $3.04 and a 12-month high of $5.53. The stock has a market capitalization of $225.39, a price-to-earnings ratio of -4.57 and a beta of 2.04.
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.